| Course | NSG 520 Pathophysiology and Pharmacology |
|---|---|
| Unit | Unit 5 |
| Paper type | Site of action comparison |
| Length | About 880 words, 6 pages |
| Format | APA 7 student paper |
| School | Herzing University |
| Program | MSN |
| Updated | October 2026 |
Free sample paper for NSG 520 Unit 5
Seven Glucose-Lowering Drug Classes Placed on One Pathway: Where Each Acts, and Why That Predicts Hypoglycemia, Weight, and Fit for a Patient With Kidney Disease
Student Name
Department of Nursing, Herzing University
NSG 520: Pathophysiology and Pharmacology
Instructor Name
February 18, 2026
Seven Glucose-Lowering Drug Classes Placed on One Pathway: Where Each Acts, and Why That Predicts Hypoglycemia, Weight, and Fit for a Patient With Kidney Disease
The Pathway, Written Out in Steps
In type 2 diabetes, blood glucose rises because several steps that normally hold it in range fail together, a view summarized as a set of defects spread across multiple organs (DeFronzo, 2009). Written as a pathway from eating to blood glucose, the steps are:
Step A: carbohydrate is digested and absorbed in the small intestine. Step B: the gut releases incretin hormones, chiefly glucagon-like peptide 1, which are rapidly broken down by the enzyme dipeptidyl peptidase 4. Step C: pancreatic beta cells secrete insulin, in type 2 diabetes insufficiently for the level of glucose. Step D: pancreatic alpha cells secrete glucagon, inappropriately high in type 2 diabetes. Step E: the liver releases glucose, excessive in type 2 diabetes, especially overnight. Step F: muscle and fat take up glucose in response to insulin, reduced by insulin resistance. Step G: the kidneys filter glucose and reabsorb nearly all of it, with increased reabsorption capacity in diabetes.
Every agent below is placed on one or more of these steps.
The Agents, Placed on the Pathway
The table places each class on the step or steps where it acts, and derives from that site its main consequences.
| Class, example | Step acted on | How | Hypoglycemia risk on its own | Weight |
|---|---|---|---|---|
| Alpha-glucosidase inhibitor, acarbose | A | Slows carbohydrate breakdown in the gut | Low | Neutral |
| GLP-1 receptor agonist, semaglutide | B, C, D, and satiety | Mimics the incretin: glucose-dependent insulin release, less glucagon, slower gastric emptying, less appetite | Low | Loss |
| DPP-4 inhibitor, sitagliptin | B, then C and D | Slows incretin breakdown, raising the body's own incretin levels modestly | Low | Neutral |
| Sulfonylurea, glipizide | C | Closes beta-cell potassium channels, releasing insulin regardless of glucose level | High | Gain |
| Biguanide, metformin | E, mainly | Reduces hepatic glucose production | Low | Neutral or slight loss |
| Thiazolidinedione, pioglitazone | F, mainly | Activates a nuclear receptor that increases insulin sensitivity in fat and muscle | Low | Gain; fluid retention |
| SGLT2 inhibitor, dapagliflozin | G | Blocks renal glucose reabsorption, excreting glucose in urine | Low | Loss |
What the Sites Predict
Hypoglycemia. The pattern follows from whether the drug's action depends on glucose. GLP-1 receptor agonists and DPP-4 inhibitors increase insulin secretion only when glucose is elevated, because the incretin effect is glucose-dependent (Drucker & Nauck, 2006). Metformin, acarbose, pioglitazone, and SGLT2 inhibitors do not stimulate insulin secretion at all. Sulfonylureas close the beta-cell potassium channel directly, releasing insulin whether glucose is high or low, which is why they, along with insulin itself, carry the highest risk of hypoglycemia.
Weight. Sulfonylureas and insulin raise insulin levels, which promotes storage, and pioglitazone expands fat tissue and retains fluid, so all three tend to cause weight gain. GLP-1 receptor agonists act on satiety in the brain and slow gastric emptying, producing weight loss. SGLT2 inhibitors cause a steady loss of calories in the urine.
Where Insulin Sits
Insulin is not placed on a single step because it replaces the output of step C and acts at steps E and F: it suppresses hepatic glucose production and drives glucose uptake into muscle and fat. That breadth is why it lowers glucose more than any other agent and without a ceiling, and it is also why its hypoglycemia risk is the highest: it acts whatever the glucose level. Basal insulin, given once daily, mainly suppresses overnight hepatic output at step E; mealtime insulin covers the rise after eating. In kidney disease, insulin itself is partly cleared by the kidney, so its effect lasts longer as filtration falls, and doses often need to be reduced. For a patient like Mrs. D., insulin would be the step after the oral and injectable agents above, and the pathway explains why it would come with more monitoring: it is the one agent that bypasses every safeguard the body's own glucose sensing provides.
What the Sites Predict About the Kidney
Because SGLT2 inhibitors act at step G, in the kidney, their glucose-lowering effect falls as filtration falls: with less glucose filtered, less can be blocked from reabsorption. Their kidney-protective effect, which comes from restoring tubuloglomerular feedback rather than from glucose lowering, does not fall in the same way. Metformin acts in the liver but is cleared unchanged by the kidney, so its dose must be reduced as filtration falls. Glipizide acts at the beta cell and is cleared by the liver to inactive metabolites, so it is safer in kidney disease than sulfonylureas with active metabolites cleared by the kidney, though its hypoglycemia risk remains. GLP-1 receptor agonists act largely outside the kidney and are generally usable in chronic kidney disease, with trial evidence of kidney benefit for some agents.
Applying the Comparison to Mrs. D.
Mrs. D., the composite patient whose diabetes has damaged her kidneys, takes metformin at a reduced dose (step E), glipizide at a reduced dose (step C), and dapagliflozin (step G). Her glycated hemoglobin is 7.4%. If she needs further lowering, the pathway suggests adding an agent at a step not yet covered and whose action is glucose-dependent, to avoid adding hypoglycemia risk: a GLP-1 receptor agonist, acting at steps B through D and on appetite, fits, and would also help her weight. Current standards of care recommend both GLP-1 receptor agonists and SGLT2 inhibitors for diabetic patients with kidney disease because they protect organs, independent of glucose lowering (American Diabetes Association Professional Practice Committee, 2024). If a GLP-1 receptor agonist is added, the glipizide, the drug on the pathway with the highest hypoglycemia risk, would be the first candidate to stop.
What the Pathway Leaves Out
The comparison places agents by their principal sites of action, but several act at more than one step, and the pathway omits effects beyond glucose, such as cardiovascular outcomes, that now drive many choices. It also omits cost and route: GLP-1 receptor agonists are injected or taken as a daily tablet under specific conditions, and cost limits access for many patients. The pathway explains mechanism; the final choice for a patient also weighs these.
References
American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2025. Diabetes Care, 48(Suppl. 1), S181-S206. https://doi.org/10.2337/dc25-S009
DeFronzo, R. A. (2009). From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes, 58(4), 773-795. https://doi.org/10.2337/db09-9028
Drucker, D. J., & Nauck, M. A. (2006). The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet, 368(9548), 1696-1705. https://doi.org/10.1016/S0140-6736(06)69705-5
Reading the NSG 520 Unit 5 instructions
Unit 5 asks you to compare several drug classes by where they act on one pathway. Expect to write the pathway in steps, place each class on its step, derive predictions about benefits and risks from the sites, apply the comparison to a patient and note what the pathway leaves out. Students often ask how many classes to include and how detailed the pathway should be. Seven classes covers current diabetes treatment well. Letter the steps so the table can refer to them. Predictions should follow from mechanism, such as glucose-dependent action lowering hypoglycemia risk. Kidney function changes the value of drugs that act in the kidney. Note drugs that act at more than one step.
How the NSG 520 Unit 5 example is put together
The comparison opens with the pathway in lettered steps. The table places each class on its step with the predicted effects on glucose, hypoglycemia, weight and kidney. The prediction section explains each pattern by mechanism. The insulin section explains why it does not fit a single step. The kidney section explains that SGLT2 glucose lowering fades as filtration falls while kidney protection continues. The patient section applies the table to Mrs. D.'s regimen and kidney function. The limits section notes drugs with several sites. Every prediction points back to a step, which is what makes the comparison more than a drug list.
NSG 520 Unit 5 rubric: what full points look like
Herzing's rubric for a site of action comparison typically covers the pathway, placement of each class, predictions from sites, application to a patient and limits. Most marks go to predictions reasoned from each drug's site, such as low hypoglycemia risk for glucose-dependent agents. Pathway points reward accurate, ordered steps that the table can refer to by letter. Placement criteria look for each class on the correct step. Prediction points go to hypoglycemia, weight and kidney effects explained by mechanism. Application earns credit when kidney function and the patient's current drugs shape the reading. Limits points go to drugs that act at more than one site. Noting cardiovascular benefits where trials show them usually earns credit, and the table should be easy to scan. The ADA Standards of Care support the predictions.
NSG 520 Unit 5 help: mistakes that cost points
Site comparisons in Unit 5 commonly lose points by listing drug classes with side effects but no pathway. Another frequent problem is placing a class on the wrong step, such as metformin on insulin secretion. Students often miss why GLP-1 agonists rarely cause hypoglycemia on their own. Kidney effects are ignored, though they change drug choice in Mrs. D. Insulin is forced onto one step. The patient application is missing. Weight effects are not explained by mechanism. Cardiovascular and kidney outcome trials are not mentioned. Combination risks, such as a sulfonylurea with insulin, are left out. Finally, derive every prediction from a site, because graders reward a comparison that would let a student predict effects for a new drug class.
Get a NSG 520 Unit 5 example written to your instructions
Send the Unit 5 instructions and the rubric from your NSG 520 classroom, and name the condition and the classes your course puts in scope. We write a custom example that builds the shared pathway first, places every class on a step, derives properties from position and closes on the steps nothing targets. First custom sample free, back in 24 to 48 hours.
More NSG 520 papers and MSN samples
- NSG 520 Unit 1: Cellular mechanism trace
- NSG 520 Unit 2: Dosing principle worksheet
- NSG 520 Unit 3: Two science integration case
- NSG 520 Unit 4: Receptor distribution study
- NSG 520 Unit 6: Abnormal value interpretation table
- NSG 520 Unit 7: Plain language mechanism explainer
- NSG 520 Unit 8: Foundational sciences portfolio
- NSG 521 Unit 5: Basic care activity rationale
- NU 700 Unit 5: Evidence appraisal
- NU 725 Unit 5: Usability review
- NU 726 Unit 5: Advocacy brief
NSG 520 Unit 5 questions, answered
Is a table enough for this deliverable?
A table organizes the comparison but rarely carries it. The reasoning lives in why a class sits where it does and what follows from that position, and those are sentences. Where your instructions ask for a table, write it and then explain the column that matters most, since a grid of properties with no argument attached reads as a transcription exercise.
How many agents should the comparison hold?
Enough to cover the distinct steps in the pathway, which is usually three or four classes rather than every option available. Adding a class that acts where one already discussed acts buys little unless you separate them on a second criterion. Depth on placement scores better than breadth in a unit built around mechanism.
What if two classes act at the same step?
That is a useful case rather than a problem. Say they share the step, then separate them on something the pathway does not settle: handling by the body, duration, the route available, or which downstream effect predominates. Naming the second criterion explicitly is the move that turns a coincidence into an argument the criteria can read.
Where can I find a free NSG 520 Unit 5 sample paper?
The full NSG 520 Unit 5 site of action comparison is free on this page, seven diabetes drug classes placed on one pathway with predictions. A comparison for another drug group can be prepared on request.
Why do some diabetes drugs cause low blood sugar and others don't?
Drugs whose action depends on glucose, such as GLP-1 agonists and DPP-4 inhibitors, rarely cause lows alone, while sulfonylureas and insulin act regardless of glucose. This sample derives that pattern from where each class acts.